Search

International audience; Objective: Salivary gland tumors (SGTs) are one of the most heterogeneous and challenging neoplasms affects human. Severalbiomarkers have been used to study proliferation, angiogenesis, prognosis, metastasis and recurrence of SGTs. The aim of this studywas to evaluate, compare and correlate the co-expression of Budding Uninhibited by Benz imidazole Related 1 (BubR1) andUbiquitin C-terminal hydrolase-L1 (UCHL1) immunomarkers in SGTs.Methods: The immunohistochemical expression of BubR1 and UCHL1 were performed with formalin fixed paraffin embeddedtissue sections of 35 retrieved blokes of SGTs. The expression, pattern of reactivity, intensity and subcellular localization of thesemarkers are studied. T-test was used to find statistical difference in expression immunomarkers.Results: All of the cases were positive for both BubR1 and UCHL1. The intensity of reaction differed between the tumor types. Asignificant difference was seen in the expression of BubR1 in benign versus malignant tumors (P=.002) and pleomorphic adenomaversus mucoepidermoid carcinoma (P=.001). While statistically significant difference was not seen in the expression of UCHL1between the tumors mentioned above (P=.81 and P=.83, respectively). Finally, there was a significant difference between theexpressions of BubR1 and UCHL1 in SGTs (P=.001), indicating a higher expression of UCHL1 in SGTs.Conclusions: UCHL1 has a higher percentage and intensity of reactivity in SGTs as compared to BubR1, While BubR1 is a betterimmunomarker for distinguishing between benign and malignant tumors.